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Abstract 
It is well-established that FKBP51 regulates the stress system by modulating the sensitivity 
of the glucocorticoid receptor to stress hormones. Recently, we have demonstrated that 
FKBP51 also drives long-term inflammatory pain states in male mice by modulating 
glucocorticoid-signalling at spinal cord level. Here, we explored the potential of FKBP51 as a 
new pharmacological target for the treatment of persistent pain across the sexes. First, we 
demonstrated that FKBP51 regulates long-term pain states of different aetiologies 
independently of sex. Deletion of FKBP51 reduced the mechanical hypersensitivity seen in 
joint inflammatory and neuropathic pain states in female and male mice. Furthermore, 
FKBP51 deletion also reduced the hypersensitivity seen in a translational model of 
chemotherapy-induced pain. Interestingly, these three pain states were associated with 
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changes in glucocorticoid signalling, as indicated by the increased expression, at spinal cord 
level, of the glucocorticoid receptor isoform associated with glucocorticoid resistance, GRβ, 
and increased levels of plasma corticosterone. These pain states were also accompanied by 
an up-regulation of interleukin-6 in the spinal cord. Crucially, we were able to 
pharmacologically reduce the severity of the mechanical hypersensitivity seen in these three 
models of persistent pain with the unique FKBP51 ligand SAFit2. When SAFit2 was combined 
with a state-of-the-art vesicular phospholipid gel formulation for slow release, a single 
injection of SAFit2 offered pain relief for at least 7 days. We therefore propose the 
pharmacological blockade of FKBP51 as a new approach for the treatment of persistent pain 
across sexes, likely in humans as well as rodents. 
 
Summary 
Pharmacological blockade of FKBP51 can reduce established persistent pain states across 
sexes. 
 
Keywords 
FKPB51; dorsal horn; glucocorticoid receptor; glucocorticoid signalling; persistent pain; 
stress; interleukin-6; corticosterone; pharmacological inhibition; paclitaxel; vesicular 
phospholipid gel. 
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1. INTRODUCTION 
The FK506 binding protein 51 (FKBP51) is important for the regulation of the stress response 
and polymorphisms of the FKBP51-encoding gene, FKBP5, have been associated with 
atypical stress axis reactivity, with high levels of FKBP51 protein associated with a hyper-
reactive stress pathway often seen in patients with depression [5,43]. Supporting these 
observations, deletion of FKBP5 in mice leads to a reduction in corticosterone secretion and 
anxiety-related behaviours [17,18]. FKBP51 is a co-chaperone that changes folding and 
activity of other proteins. It modulates the stress axis, also called the hypothalamic-
pituitary-adrenal (HPA) axis, through binding of the steroid complex and inhibition of the 
glucocorticoid receptor (GR) function [43]. While it remains unclear whether FKBP51-
binding to the steroid complex directly inhibits GR function [12], by regulating GR signalling 
FKBP51 can modulate the actions of glucocorticoids, including the expression of 
glucocorticoid-responsive genes and the GR-mediated negative feedback of the HPA axis 
[43]. 
Traumatic events are powerful stressors that can activate the HPA axis and thereby are 
likely to contribute to the development of persistent posttraumatic pain in vulnerable 
individuals [13,23,29]. Supporting this hypothesis, variations in FKBP5 associated with 
enhanced induction of FKBP5 mRNA by cortisol and reduced GR sensitivity [4,5] were 
associated with increased musculoskeletal pain after motor vehicle collision or sexual 
assault [7]. Interestingly, the association between the reported pain and the FKBP5 gene 
variations was stronger 6 weeks after trauma than immediately after trauma, suggesting 
that FKBP5 was more likely to contribute to persistent than acute pain states [7]. 
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Consistent with these findings, we have recently demonstrated that FKBP51 is expressed in 
rodent dorsal horn where it plays a key role in the full development and maintenance of 
chronic joint inflammatory pain [15,21], but has no effect on acute pain responses. FKBP5 
knock-out (KO) male mice with an inflamed joint had reduced pain compared with their 
wild-type (WT) littermates and inhibition of FKBP51 at spinal level, using siRNA, significantly 
attenuated pre-existing joint inflammatory pain. The expression of FKBP51 was significantly 
reduced in the dorsal horn by intrathecal delivery of the siRNA but left intact in DRGs, 
indicating that FKBP51 expressed in DRGs was unlikely to contribute to the maintenance of 
the pain state. Moreover, FKBP51 modulation of long-lasting mechanical hypersensitivity 
occurred through the regulation of GR signalling [21], a signalling pathway previously shown 
to regulate the hypersensitivity seen in long-term pain states at spinal cord level [33,39,40]. 
Finally, the deletion of FKBP51 was associated with a reduced expression at spinal cord level 
of the cytokine interleukin-6 (IL6) which is up-regulated in chronic pain states [44] and 
under transcriptional control of GR [27,38]. 
Here, we have used molecular and pharmacological tools to investigate the regulation of 
permanent pain states of different aetiology by FKBP51, in both male and female mice. It 
has been suggested that the mechanisms of development of chronic pain states differed 
between sexes, implying a potential need for different strategies to address chronic pain in 
men and women [2,32]. It was therefore crucial to investigate whether FKBP51 drove 
permanent pain states across sexes. 
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2. MATERIAL AND METHODS 
 
2.1 Animals 
Subjects in all experiments were adult male and female mice (8-12 weeks old). Mice were 
FKBP51 KO and their WT littermates obtained from FKBP51 heterozygous from C.A. Dickey’s 
group (University of South Florida, USA). These mice were from mixed genetic background, 
C57Bl/6J and Swiss Webster. All animals were kept in their home cages in a temperature-
controlled (20 ±1 ºC) environment, with a light-dark cycle of 12h (light on at 7:30 a.m.) food 
and water were provided ad libitum. All efforts were made to minimise animal suffering and 
to reduce the number of animal used (UK Animal Act, 1986). 
 
2.2 Genotyping 
For genotyping, DNA was extracted from a small portion of ear tissue. Each sample was 
lysed in 75 μl of Alkaline Lysis buffer (25 mM NaOH, 0.2 mM EDTA, pH 12) and heated at 
95˚C for 30 min. After cooling, 75 μl of neutralising reagent (40 mM Tris-HCl, pH 5) were 
added to each sample. The following primers were used for the PCR: forward primer (for WT 
and 51KO): AAAGGACAATGACTACTGATGAGG; reverse WT primer: 
AAGGAGGGGTTCTTTTGAGG; reverse 51KO primer: GTTGCACCACAGATGAAACG. 
Amplification was obtained starting from 1 μl of DNA and one unit of Taq DNA polymerase 
(Promega, Madison, USA) in a final volume of 20 μl of amplification buffer. 15 μl of products 
obtained by amplification were loaded on a 2% agarose gel containing 20 μl ethidium 
bromide, subjected to electrophoresis and visualized under a UV light. Samples from WT 
animals showed a single PCR product of 363bp; samples from KO animals showed a single 
PCR product of 510bp and samples from HET animals presented both bands. 
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2.3 Pain models 
2.3.1 CFA induced ankle joint inflammation 
Inflammation was induced by injection of Complete Freud’s Adjuvant (CFA; Sigma, UK) at 
the volume of 5 μl, in the left ankle joint, under isoflurane anaesthesia induced in a chamber 
delivering 2% isoflurane combined with 100% O2 and maintained during injection via a face 
mask. The needle entered the ankle joint from the anterior and lateral posterior position, 
with the ankle kept in plantar flexion to open the joint. Sham treatment consisted of 
anesthetizing the animals.  
2.3.2 Neuropathic model: spared nerve injury 
The spared nerve injury (SNI) was performed as previously described [11,21]. Briefly, under 
isoflurane anaesthesia, the skin on the lateral surface of the thigh was incised and a section 
made directly though the biceps femoris muscle exposing the sciatic nerve and its three 
terminal branches: the sural, the common peroneal and the tibial nerves. The common 
peroneal and the tibial nerves were tight-ligated with 5-0 silk and sectioned distal to the 
ligation. Great care was taken to avoid any contact with the spared sural nerve. Complete 
haemostasis was confirmed and the wound was saturated. Sham treatment consisted of 
exposing the sciatic nerve only. 
2.3.3 Chemotherapeutic-induced neuropathic pain: Paclitaxel 
To induce mechanical hypersensitivity, paclitaxel was injected under isoflurane anaesthesia 
as previously described [26]. Paclitaxel (Sigma, UK) was dissolved in a solution made up of 
50% Cremophor EL (Sigma, UK) and 50% absolute ethanol and stored at -20˚C, for a 
maximum of 14 days, and was diluted in normal saline (NaCl 0.9%), just before 
administration. The vehicle for Paclitaxel, 50% Cremophor EL and 50% absolute ethanol, was 
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diluted, at the time of injection, with saline. Paclitaxel (2mg/Kg) was injected 
intraperitoneally (i.p.), on alternating successive days (days 0, 2, 4, and 6). No weight loss or 
mortality was observed in paclitaxel-treated mice throughout the experiments.  
 
2.4 Behavioural testing 
N.B: the experimenter was always blind to genotype and treatment. 
Von Frey’s Hairs 
Animals were placed in plexiglas chambers, located on an elevated wire grid, and allowed to 
habituate for at least 1 hour. After this time, the plantar surface of the paw was stimulated 
with a series of ascending forces Von Frey’s monofilaments. The threshold was determined 
by using the up-down method as described by Chaplan and colleagues [10]. The data were 
expressed as log of the mean of the 50% pain threshold ± SEM. 
 
2.5 Intrathecal injections 
The intrathecal injections were performed as previously described [21]. Briefly, under 
anaesthesia, mice were held firmly, but gently, by the pelvic girdle using thumb and 
forefinger of the non-dominant hand. This grip caused the hind legs to splay outward and 
downward. The skin above the iliac crest was pulled tautly to create a horizontal plane 
where the needle was inserted. Using the other hand, the experimenter traced the spinal 
column of the mouse, rounding or curving the column slightly to open the invertebrate 
spaces. A 30-gauge needle connected to a 10 μl Hamilton syringe was used to enter 
between the vertebrae. After injection, the syringe was rotated and removed and posture 
and locomotion were checked. All intrathecally delivered drugs were injected in a 2 μl 
volume. 
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2.6 Drugs 
Mifepristone (1 nmol in 2 μl) was purchased from Sigma and was dissolved in 10% ethanol in 
saline. Control animals received 2 μl of 10% ethanol in saline. SAFit2 was synthesized as 
previously described [14] and used at a concentration of 2mg/ml in Vehicle A (4% Ethanol, 
5% PEG400, 5% TWEEN 80 in 0.9% saline; used at 10ml/kg or 20mg/kg) or 10mg/ml in VPG = 
Vehicle B (50% (m/m) egg lecithin containing at least 80% phosphatidylcholine (PC) in 10mM 
phosphate buffered saline (PBS) pH 7.4; used at 10ml/kg or 100mg/kg) or in Vehicle C (20% 
EtOH, 40% PPG, 5% PEG400, 5% TWEEN80 in 0.9% saline; used at 10ml/kg or 100mg/kg). 
VPGs (with and without SAFit2) were prepared by a dual asymmetric centrifugation 
technique as described below. Egg lecithin (Lipoid E80) was a kind gift from Lipoid GmbH 
(Ludwigshafen, Germany). Control animals received Vehicle only. 
 
2.6.1 Preparation of VPGs by dual asymmetric centrifugation 
VPGs with a phospholipid amount of 50% (m/m) were prepared by dual asymmetric 
centrifugation (DAC). In order to encapsulate the poorly water-soluble SAFit2 into the 
formulation by a direct incorporation method, the accurately weighted phospholipid was 
solved in ethanol (100%) and SAFit2 stock solution (20.0 mg/ml in 100% ethanol) was added 
in the desired amount to the phospholipid solution. The ethanol was evaporated for two 
days in a vacuum drying oven at a temperature of 25 °C and a pressure of 10 mbar. Then the 
solid mixture was hydrated with the accurate amount of 10mM phosphate buffer saline 
(PBS) buffer pH 7.4 and homogenized by a DAC (SpeedmixerTM DAC 150.1 FVZ, Hauschild 
GmbH &Co KG, Hamm, Germany).  
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DAC is a double centrifugation technique which is perfectly suited for the mixing of highly 
viscous formulations and has been used in the past to prepare liposomes and fat-emulsions 
[19,35]. Its application to manufacture VPGs has been first described by Massing et al in 
2008 [22]. In this technique the container is not only spun around the commonly known 
centrifugation axis in the middle of the centrifuge but also around a second axis in the 
middle of the container. Due to the two counter-rotating movements, high shearing forces 
and a homogenous mixture of the components are achieved. 
For homogenization of the phospholipids and buffer in our study, a process speed of 
3500rpm was utilized. A custom made cooling system was installed to prevent the material 
from heating during the continuous mixing over 45 minutes. The final amount of SAFit2 in 
the formulation was 10 mg/g. 
The described manufacture process was used for the preparation of a second VPG 
formulation without the addition of SAFit2 stock solution as a control formulation (Vehicle 
B). 
 
2.6.2 Preparation of a SAFit2 solution with a concentration of 10 mg/ml 
A non-retarded SAFit2 control solution was prepared to evaluate the depot effect of SAFit2-
VPG. Therefore, Vehicle C (20% ethanol, 40% propylene glycol, 5% polyethylene glycol 400 
and 5% Tween 80 in 0.9% saline) was needed to allow dissolving SAFit2 in a concentration of 
10mg/ml. Utilizing this formulation, the direct comparison of the subcutaneous injection of 
the exact same dose and injection volume of SAFit2 solution and SAFit2-VPG was possible. 
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2.7 Blood sampling and corticosterone assay  
Blood was collected in the morning between 9:00 to 11:00 from the mouse tail vein. Before 
sampling, mice were placed in a warming cabinet (39˚C for 10 to 15 min) in order to dilate 
the blood vessel. The levels of corticosterone were measured using an ELISA kit (ab108821, 
Abcam, Cambridge, UK) following the manufacturer protocol. 
 
2.8 Fresh tissue collection and RNA preparation 
For fresh tissue collection, animals were terminally anesthetized with CO2 3 d after CFA or 
sham surgery. The spinal cord segment corresponding to the lumbar area was rapidly 
removed, and the ipsilateral dorsal horn quadrant L4-L6 were dissected out and frozen on 
dry ice. Samples were then stored at -80˚C until further processing. Total RNA was extracted 
using an acid phenol extraction method (TRIzol reagent, RNeasy mini-columns; Quiagen, 
UK). RNA concentration was measured with the Nanodrop (Labtech International, Ringmer, 
UK). 
 
2.9 RTqPCR 
RNA samples were treated with DNase I (Quiagen, Crewley, UK). Equal amounts (between 
200 and 500ng depending on the set of experiments) of total RNA were reversed 
transcribed using random nonamers (Sigma, Poole, Uk), Oligo(dT)20 primers (Promega, WI, 
US) and Superscript TM III RT (Invitrogen, Carlsband, CA, US) for 1 h at 50ºC in a total 
reaction volume of 20 μl. cDNAs were immediately used for qPCR or kept at -20ºC; qPCR 
reactions were performed with DNA Engine (BioRad, CA) using SYBR Green JumpStart Taq 
ReadyMix (Sigma, MO, UK) and gene-specific primer sets (primer sequences available on 
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request). One μl of cDNA diluted 1/10 in H2O was amplified in a three step cycling program 
in a final reaction volume of 25 μl. Control cDNA samples obtained without transcriptase 
were always included, as well as samples without any cDNA template. Reactions were 
performed at least in triplicate and the specificity of the products was determined by 
melting curve analysis. The ratio of the relative expression of target genes to β-actin was 
calculated by using the 2∆Ct formula. Efficiencies of qPCRs were calculated for each gene 
using serial dilution. 
 
2.10 Immunohistochemistry 
For immunohistochemistry, mice were deeply anesthetized with pentobarbital and perfused 
transcardially with saline containing 5000 IU/ml heparin followed by 4 % paraformaldehyde 
(PFA) in 0.1 M phosphate buffer (PB; 25ml per adult mouse). Lumbar spinal cords were 
dissected out, postfixed in the same PFA solution for 2 h, and transferred into a 30 % 
sucrose solution in PB containing 0.01 % azide at 4˚C, for a minimum of 24 h. Spinal cords 
were cut on a freezing microtome set at 40 μm. 
For fluorescent immunohistochemistry, sections were left to incubate with primary 
antibodies O/N at room temperature (anti-FKBP51, 1:5000, Santa-Cruz #sc11518; anti-IL6, 
1:5000, Abcam #ab6672). Appropriate biotinylated secondary antibody was used at the 
concentration of 1:400 and left for 90 min. Sections were then incubated with avidin biotin 
complex (ABC Elite, Vector Lab; 1:250 Vectastain A plus 1:250 Vectastain B) for 30 min 
followed by a signal amplification step with biotinylated tyramide solution (TSA; 1:75 for 7 
min; Perkin Elmer, Wellesley, MA). Finally sections were incubated with FITC avidin for 2h 
(1:600). For multiple labelling, other primary antibodies were left O/N at room temperature 
at the end of the TSA protocol (anti-Iba1 1:1500, Wako, Osaka, Japan; anti-GFAP 1:4000, 
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DAKO, Cambridge, UK; anti-NeuN: 1:1000) and revealed the following day with appropriate 
direct secondary antibody at a concentration of 1:500 (Alexa Fluor). Finally, sections were 
incubated with the acid nucleic marker To-pro, as per manufacturer instructions. All 
fluorescent sections were coverslipped with Gel Mount Aqueous Mounting Medium (Sigma) 
to protect the fluorescence from fading and stored in dark boxes at +4ºC.  
For β-galactosidase and DAB staining, spinal cords were sectioned on a freezing microtome 
set to 20µm. Free-floating sections were incubated in warmed X-gal working solution (X-gal 
stock; X-gal, Chem-Cruz #sc280488, in DMF; diluted in X-gal dilution buffer; 5mM potassium 
ferricyanide crystalline, 5mM potassium ferricyanide trihydrate, 2mM magnesium chloride  
in PB; 1:40) at 37˚C for 1.5 hours. Following the stain, the sections were washed in PB and 
then water for 5 minutes each. To achieve double labelling, DAB (3,3′-Diaminobenzidine) 
staining was used. First, the sections were blocked in PB with 3% serum, 3% triton and 2% 
H2O2 for one hour, and then incubated in the chosen primary antibody either O/N (anti-
NeuN, 1:1000, Millipore #MAB377; anti-NG2, 1:500, Millipore #MAB5384; anti-APC, 1:200, 
Calbiochem #OP80) or for 72hrs (anti-Iba1, 1:500, Wako, Osaka, Japan). The sections were 
then incubated in appropriate secondary antibodies at 1:500 for 2 hours, followed by 
incubation with avidin biotin complex (ABC Elite, Vector Lab; 1:1000 Vectastain A plus 
1:1000 Vectastain B) for 1 hour. The substrate was then developed using a peroxidase 
substrate DAB kit (Vector #SK4100) at optimised times, and the sections were washed and 
mounted. The following day, the sections were dehydrated in increasing ethanol 
concentrations (70%, 70%, 95%, 95%, 100%, 100%, histoclear x2) and coverslipped with 
DPX. For the FKBP51 double DAB labelling, the sections underwent an initial DAB staining 
with a chosen primary antibody, as previously described. The sections were then incubated 
in anti-FKBP51 (1:500, Santa-Cruz #sc11518) for 72 hours and a second DAB staining 
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procedure was completed, with the addition of a Nickle solution to the substrate mixture, in 
order to produce the distinguishable grey stain. 
 
2.11 Image analysis 
Fluorescent images: confocal imaging and analysis 
All fluorescent images of quadruple stain tissue were acquired by confocal microscopy using 
a laser-scanning microscope (Leica TCS NT SP). Sequential laser channel acquisition was used 
to prevent the generation of false positives by ‘bleed through’ of immunofluorescence from 
one channel to the other. For quantitative analysis of cell specific expression of FKBP51, 
single plan images were acquired with an ACS APO 40.0x oil objective (Fig.2B,C). A single 
picture per section side was taken spanning lamina I to III. Offset, gain and laser strength of 
each scan was not changed throughout the imaging. 5 dorsal horn sections were imaged per 
animal for each ipsilateral and contralateral side, n=3/group. Cell specific expression was 
manually quantified from confocal images and individual optical plan inspection. For a cell 
(neurone, astrocyte or microglia) to be considered positive for FKBP51, the expression of 
FKBP51 had to appear together with the cell specific marker (or surrounded by the cell 
specific marker for Gfap), and with the nucleic acid stain To-pro which labels au nuclei. We 
quantified the number of neurones, astrocytes and microglia positive for FKBP51 and 
expressed it as a percentage of total number of neurones, astrocytes or microglia. 
 
β-galactosidase and DAB images 
Images of β-galactosidase and DAB tissue were acquired using a Zeiss Axio Scan Z1 Slide 
Scanner bright field microscope. This would not allow the dissection of individual optical 
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channels. Entire spinal cord sections were imaged using this system, with 5 to 6 dorsal horn 
sections imaged per animal, n=3/group. Cell specific expression was manually quantified 
from acquired images. For a cell (neurone or microglia) to be considered positive for 
FKBP51, X-gal stain had to appear within the cell specific marker (NeuN or Iba1). We 
quantified the number of neurones and microglia positive for FKBP51 and expressed it as a 
percentage of total number of neurones or microglia. 
 
2.12 Data analysis 
All statistical tests were performed in IBM SPSS statistic 20. For the behavioural 
experiments, statistical analysis was performed on the data normalized by log 
transformation (Von Frey data; as suggested by Mills et al. [25]). The significance of any 
differences in sensitivity was assessed using repeated-measured two-way or one-way 
ANOVA, as appropriate. In all cases, a significant effect of the main factor(s), or interactions 
between them, was taken as the criterion for progressing to post hoc analysis. Bonferroni 
analysis was the preferred post-hoc analysis; however, if the general ANOVA was significant 
but no Bonferroni significance observed, we also reported the results of the LSD post-hoc 
analysis. In all cases ‘time’ was treated as a within subjects factor and ‘genotype’ and 
‘treatment’ were treated as between subject factors. For the RTqPCR experiments, data 
were analysed by univariate analysis for individual genes followed by the appropriate post-
hoc analysis (1-way ANOVA or t-test). Biological samples for the measures of glucocorticoid 
levels were analysed by 2-way ANOVA and appropriate post-hoc analysis. 
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2.13 Study Approval 
All procedures described in this manuscript comply with the United Kingdom Animals 
(Scientific Procedures) Act 1986 and the research was performed under strict Home Office 
regulations, under the project licence PPL 70/7944. 
 
3 RESULTS 
3.1 FKBP51 deletion significantly attenuates the development of mechanical 
hypersensitivity in long-term pain states across sexes 
3.1.1 Inflammatory pain states  
We first examined whether FKBP51 regulated the development of the mechanical 
hypersensitivity seen with ankle joint inflammation in female mice via modulation of 
glucocorticoid signalling, as we have reported in male mice [21]. We first tested the effect of 
global deletion of FKBP51 on the mechanical hypersensitivity that develops after the 
injection of Complete’s Freund Adjuvant (CFA) in the ankle joint. Global deletion of FKBP51 
in female mice did not affect their basal mechanical threshold when compared to WT mice 
(Fig.1A). However, following CFA injection in the ankle joint, while both WT and KO mice 
showed a significant decrease in mechanical sensitivity, the effects observed in KO mice 
were significantly less severe than in WT mice (Fig.1A), as previously observed in males [21]. 
Next, using RT-qPCR, we measured a significant increase in spinal FKBP51 mRNA in WT 
female mice after induction of joint inflammation with CFA (Fig.1B), consistent with our 
previous findings [21]. This increase was accompanied by an up-regulation of IL6 and of the 
GR isoform associated with glucocorticoid resistance [20], GRβ (Fig.1B), suggesting that 
glucocorticoid signalling was likely to contribute to the development of this long-term pain 
state in females, as seen in males.  
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Crucially, FKBP51 and IL6 were not up-regulated in the dorsal horn of mice following IL6 
injection in the hindpaw (for FKBP51: sham 100 ± 7 vs IL6-treated ipsi: 120 ± 21; for IL6: 
sham 100 ± 14 vs IL6-treated ipsi: 149 ± 41; Mean ± SEM, 24h post IL6, data normalised to 
WT; n=6/6). Injection of IL6 in the hindpaw induces short-term inflammation which is not 
modulated by FKBP51 (no differences in behaviour between FKBP51 KO and WT mice), but 
induces a mechanical hypersensitivity of a similar degree than that seen with ankle joint 
inflammation [21]. 
Finally, we tested the hypothesis that glucocorticoid signalling contributes to the 
development of CFA-induced joint pain in female mice and investigated whether FKBP51 
regulation of this pain state occurred via the modulation of glucocorticoid signalling. For 
this, we used the GR antagonist mifepristone (RU38486). When mifepristone was 
administered intrathecally 3 days after CFA injection in the ankle joint, there was a rapid 
reduction in the CFA-induced hypersensitivity in WT mice (Fig.1C), indicating that GR 
signalling was crucial to the full manifestation of the hypersensitivity. However, we 
observed an increase in the hypersensitivity in FKBP5 KO mice after mifepristone (Fig.1C), 
indicating that, following FKBP5 deletion, GR signalling in long-term pain states was anti-
nociceptive. All together, these results were consistent with our findings in males and 
demonstrated that FKBP51 regulates inflammatory pain states in a sex independent manner 
and, at least partly, by modulating GR signalling and possibly through the regulation of IL6 
expression. Supporting this idea, we observed that IL6 was mainly expressed in neurones in 
the superficial dorsal horn of mice with an inflamed joint (Fig.S1, available online as 
supplemental digital content at http://links.lww.com/PAIN/A550), as we had previously 
reported for FKBP51 [21]. 
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3.1.2 Nerve injury 
We next investigated whether FKBP51 also regulated neuropathic pain states across sexes. 
Both KO male and KO female mice were less sensitive than their sex-matched WT 
littermates to neuropathic pain induced by Spared Nerve Injury (SNI) [11] (Fig.2A). There 
was no difference between females and males mechanical thresholds both at baseline and 
following surgery. 
To explore the effects of the deletion of FKBP51 on GR signalling we measured 
corticosterone levels in KO and WT mice before and after SNI, as we had done previously in 
a model of ankle joint inflammation [21]. We found that nerve injury induced an overall 
increase in plasma corticosterone levels across both genotypes (Table 1) but that plasma 
corticosterone levels were lower in KO mice both before and after nerve injury (Table 1), 
confirming our observation that FKBP5 deletion leads to the suppression of corticosterone 
secretion both in naïve mice and mice with persistent pain [21]. 
We then wanted to characterise FKBP51 protein expression in mice with nerve injury 
specifically in the superficial dorsal horn, where FKBP51 exerts its key role in the modulation 
of mechanical hypersensitivity [21]. We had previously reported than FKBP51 was mainly 
expressed in neurons of the superficial dorsal horn of mice and rats that were naïve or had 
an inflamed joint [15,21] and this was supported by others [6]. However, FKBP51 mRNA has 
also been found in cultured brain microglia [42]. Since astrocytes and microglia are activated 
in the superficial dorsal horn following nerve injury, tissue from SNI animals was particularly 
suited to investigate the expression of FKBP51 in these cell types. Using a protocol of 
amplification with tyramide and an antibody from Santa Cruz that showed not specific stain 
in FKBP51 KO mice [21], we fully characterised the expression of FKBP51 in the superficial 
dorsal horn of mice. FKBP51 expression was mainly seen in neurons with 58% ± 4% of 
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neurones expressing FKBP51 in naïve mice and 44% ± 5% of astrocytes, or 6 FKBP51-positive 
neurones for every FKBP51-positive astrocyte (Fig.2B). Following nerve injury (7 days post-
surgery), there was a significant increase in the proportion of neurones and astrocytes 
expressing FKBP51, with FKBP51 seen in 70% ± 5% of neurones on the injured side 
(F1,4=14.6, P<0.05) and 60% ± 5% of astrocytes (F1,4=9.2, P<0.05), or 7 FKBP51-positive 
neurones for every FKBP51-positive astrocyte. Microglia very rarely stained positive for 
FKBP51, with an average of 7% ± 5% of microglia positive for FKBP51, or 117 FKBP51 positive 
neurones for every FKBP51 positive microglia (Fig.2C), and no increase following nerve 
injury. There was no difference in the number of neurones, astrocytes and microglia 
expressing FKBP51 between male and female mice (data not shown). To confirm the low 
level of expression of FKBP51 in microglia, we used an X-Gal stain. The FKBP5 KO mice 
contain a β-galactosidase reporter cassette which expresses wherever the FKBP5 gene is 
normally expressed. Using this approach, we found that the gene FKBP5 was expressed in 
85% ± 1.5% of neurones and in 5% ± 1% of microglia in the dorsal horn of SNI mice (Fig.2D-
G). 
Altogether, our data suggested that FKBP51 contributes to the development and 
maintenance of mechanical hypersensitivity following nerve injury across sexes, and while 
FKBP51 is mainly expressed in neurones, astrocytic mechanisms of FKBP51 driven 
nociceptive signalling cannot be excluded. 
 
3.1.3 A model of chemotherapy induced pain. 
Here, we sought to investigate the involvement of FKBP51 in a pathological pain model 
induced by the chemotherapeutic drug paclitaxel. Paclitaxel treatment induced a significant 
decrease in mechanical sensitivity in adult mice (Fig.3A) compared with vehicle. However, 
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the effects observed in KO mice were significantly less severe than in WT mice (Fig.3B), 
indicating that FKBP51 drives paclitaxel-associated mechanical hypersensitivity. 
At the molecular level, we found that the paclitaxel-associated hypersensitivity was 
accompanied by an increase in FKBP51 expression in the superficial dorsal horn and an 
increase in GRβ expression and IL6 (Fig.3C), as observed in inflammatory pain states (Fig.1B) 
[21] and following peripheral nerve injury [44]. 
 
3.2 Pharmacological inhibition of FKBP51 significantly attenuates mechanical 
hypersensitivity in established long-term pain states 
Finally, we characterised the effect of pharmacological blockade of FKBP51 using the only 
specific ligand available for in vivo use, the FKBP51 ligand SAFit2 [1,14,17]. We have 
previously shown that one single intrathecal administration of SAFit2 (4µg in 2µl) could 
reduce the hypersensitivity induced by ankle joint inflammation in male mice for 4 hours 
[21]. Here, we explored the efficacy of various routes of administration of SAFit2 on 
established long-lasting pain states across sexes. 
A single intraperitoneal injection of SAFit2 (20mg/kg) was able to reduce injury-induced 
mechanical hypersensitivity when injected when the pain state was fully developed 3 days 
after CFA injection in the ankle joint (Fig.4A) or 5 days after SNI surgery (Fig.4B). As 
expected, the effect of a single injection of SAFit2 lasted no more than 8 hours in both 
models, and we decided to test the effect of repeated injections of SAFit2 (20mg/kg), twice 
daily, over 4 days. Following this protocol, SAFit2 significantly reduced the injury-induced 
hypersensitivity for up to 4 days in the joint inflammatory and neuropathic models (Fig.4C 
and Fig.4D). 
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To reduce animal stress and improve the efficacy of the drug treatment, we explored a 
state-of-the art method of sustained release of FKBP51 using vesicular phospholipid gels 
(VPGs) [1]. Here, SAFit2-VPG was injected subcutaneously 5 days (Fig.4E) after SNI surgery 
(SAFit2 100mg/kg). A single injection of SAFit2-VPG reduced the SNI-induced mechanical 
hypersensitivity for at least 7 days. Comparing the subcutaneous un-retarded delivery of a 
SAFit2 solution containing the same dose of SAFit2 (SAFit2 100mg/kg) (Fig.4F), we could 
confirm the depot effect of the VPG and the slow release of SAFit2 from the liposome matrix 
by diffusion, leading to a significantly sustained pharmacological effect of SAFit2. SAFit2-VPG 
had no effect in naïve mice (Fig.4G), confirming that FKBP51 did not regulate naïve 
mechanical threshold nor in CFA injected FKBP5 KO mice (Fig.4H), confirming the specificity 
of the ligand SAFit2. 
We then tested if SAFit2 could improve the mechanical hypersensitivity that develops after 
PTX treatment. Mice received a single injection of SAFit2-VPG (SAFit2 100mg/kg) 12 days 
after the first injection of PTX, when the mechanical hypersensitivity was fully established. 
As expected, SAFit2-VPG significantly reduced the mechanical hypersensitivity for at least 
5 days (Fig.4I). 
Finally, we investigated whether delayed administration of SAFit2-VPG could improve long-
term pain states that had been fully established for at least 1 week and whether repeated 
administration of SAFit2-VPG would maintain the improvement of the pain state. When 
given 12 days after nerve injury, SAFit2-VPG (SAFit2 100mg/kg) once again reduced the SNI-
induced mechanical hypersensitivity and when the injection was repeated 7 days after the 
first one, the reduced hypersensitivity was maintained for at least 16 days (Fig.4J). 
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Altogether, our data strongly suggest that FKBP51 is a promising pharmacological target for 
the treatment of persistent pain states across sexes. 
 
4 DISCUSSION 
In this study, we have demonstrated that FKBP51 was the driver of long-term pain states of 
varied aetiology but all associated with the up-regulation of IL6 at spinal cord level. This 
regulation of persistent pain states by FKBP51 was seen across sexes and occurred through 
modulation of glucocorticoid-signalling. Then, using the unique FKBP51 ligand for in-vivo 
use, SAFit2, encapsulated in a state-of-the-art vesicular phospholipid gel for slow release, 
we have shown that pharmacological inhibition of FKBP51 reduced the established 
mechanical hypersensitivity induced by joint inflammation, nerve injury and the anti-cancer 
drug paclitaxel. We therefore propose that FKBP51 is a new pharmacologically tractable 
target suitable for the treatment of persistent pain in both males and females. 
 
Here, we demonstrated that FKBP51 drives long-term pain states across sexes and 
established that a pharmacotherapy targeting FKBP51 would alleviate long-lasting pain 
states in males and females. This was a very important translational step forward since the 
mechanisms of development of chronic pain states differ between sexes and sex differences 
in analgesic response to pain treatment are often seen [2,32]. Our data however suggest 
that pharmacological inhibition of FKBP51 is sufficient to improve the mechanical sensitivity 
that develops in a variety of long-term pain states in both female and male mice. It is 
currently understood that sex differences observed in chronic pain states arise from 
differences in immune system between males and females. Immune cells are known to 
contribute to the development of chronic pain and microglial-neurones interactions in 
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particular have been thought to be crucial to the establishment of long-lasting pain states 
[3,37,41]. However, while males and females show similar microglial activation in the 
superficial dorsal horn following injury, females are not reliant on this activation for the 
development of mechanical hypersensitivity while males are [31,34]. Our observation that 
FKBP51 is mainly expressed in neurones and hardly ever seen in microglia in the spinal cord 
would argue that the mechanisms of regulation of persistent pain states by FKBP51 are 
independent of immune cells-related events that often precede neuronal changes at spinal 
cord levels in chronic pain states. 
 
At the molecular level, we found that the persistent pain states that were driven by FKBP51 
were associated with (1) changes in glucocorticoid signalling, as indicated by the increased 
expression at spinal cord level of GRβ, the GR isoform associated with glucocorticoid 
resistance [20,28] and increased levels of plasma corticosterone, and (2) an up-regulation of 
IL6 expression in the dorsal horn, as shown by our data and work from others recently 
reviewed by Zhou et al. [44]. While the requirement for intact GR signalling for the full 
development of persistent pain states has already been established [33,39,40], the 
downstream events that drive these pain states are not fully understood. The N-methyl D-
aspartate (NMDA) receptor was found upregulated in the spinal cord following chronic 
constriction nerve injury (CCI) and had been suggested as a crucial link between GR 
signalling and persistent neuropathic pain induced by CCI [40]. However, we found no 
changes in expression of the NMDA receptor following inflammation of the ankle joint (data 
not shown) at a time point where FKBP51 was up-regulated and mice hypersensitive. These 
results suggested that the NMDA receptor was unlikely to be central to the mechanisms of 
maintenance of persistent pain by FKBP51. However, our findings that IL6 was upregulated 
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in the three pain models we have studied suggest that IL6 could be a crucial link. 
Administration of IL6 can cause mechanical allodynia and intrathecal injection of anti-IL6 
neutralizing antibody can alleviate pain-related behaviours [24,44], indicating a critical role 
for IL6 in the maintenance of persistent pain states. Since GR can directly regulate IL6 
transcription by complex binding to IL6 promoter regulatory elements [38] and since the GR 
agonist dexamethasone can induce IL6 expression in rodent neurons [27], it is possible that 
the regulation of chronic pain states by FKBP51 occurs via IL6, downstream of glucocorticoid 
signalling. The fact that FKBP51 and IL6 are mainly expressed in neurones in the superficial 
dorsal horn would support this idea. Importantly, injured FKBP5 KO mice had lower levels of 
IL6 in the superficial dorsal horn after CFA injection in the ankle joint [21] and after nerve 
injury (data not shown). Moreover, IL6 is not up-regulated in the dorsal horn in short-term 
pain states that are not modulated by FKBP51, such as the inflammatory pain state initiated 
by IL6 injection in the hindpaw [21]. While the regulation of IL6 expression in the dorsal 
horn by glucocorticoid signalling remains to be demonstrated, our data certainly provide 
further support for the regulation of persistent pain states by GR signalling at spinal cord 
level. 
 
Here, we were able to replicate the effect of FKBP51 deletion on injury-induced mechanical 
hypersensitivity using the FKBP51 ligand SAFit2. Using the same doses of SAFit2 in vivo 
(20mg/kg or 100mg/kg for SAFit2-VPG), others were also able to replicate the anxiolytic 
properties FKBP51 deletion [17] and its effects on body weight regulation and glucose 
tolerance [1]. This study also showed that high and stable SAFit2 plasma levels can be 
achieved in vivo, and that the slow-release SAFit2-VPG formulation reaches plasma SAFit2 
concentrations comparable to the repeated twice daily 20mg/kg injection [1]. Importantly, 
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SAFit2 has a selectivity for FKBP51 over FKBP52 >10,000 [14] and a >500x selectivity 
windows for a panel of 43 behaviourally relevant CNS receptors 
(https://pdspdb.unc.edu/pdspWeb; unpublished data Dr. Felix Hausch). While the FKBP51 
functions modulated by SAFit2 currently remain unclear, our data could suggest that SAFit2 
modulate FKBP51 regulation of GR sensitivity. Whether SAFit2 can reverse the increase in 
IL6 observed in our animal models also remains to be investigated. 
 
Crucially, we were able to offer long-lasting pain relief in persistent pain states, in both male 
and female mice, using a single injection of SAFit2 encapsulated in a vesicular phospholipid 
gel allowing the slow release of SAFit2 [1]. VPGs are highly concentrated, semisolid 
dispersions of phospholipids in aqueous medium [8] that display excellent biocompatibility 
due to their composition of solely phospholipids and water or buffer [9] and can provide 
release rates over several weeks. VPGs have been used in the past as depot formulations for 
the sustained release of pharmaceutical drugs, including peptides and proteins [9,16,36]. 
The capability of VPGs to encapsulate water soluble drugs, as well as drugs with poor 
solubility in aqueous medium, makes them perfectly suited as a sustained release system for 
a substance like SAFit2. Hydrophobic interactions between the relatively lipophilic SAFit2 
and the phospholipids of the formulation lead to binding and incorporation of the drug in 
the hydrophobic areas of the phospholipid bilayers of the liposome matrix and SAFit2 has to 
diffuse through several densely packed hydrophilic and lipophilic compartments on its way 
out of the depot, resulting in a strong retardation. Here, SAFit2-VPG was injected 
subcutaneously, once the pain states were fully established, and was able to reduce the 
mechanical hypersensitivity for at least 7 days following a single injection, and at least 14 
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days when reinjected after 7 days, indicating that chronic inhibition of FKBP51 could offer 
long-lasting pain relief.  
 
SAFit2 resolved mechanical hypersensitivity when administrated as late as 12 days after 
nerve injury, suggesting that inhibition of FKBP51 could be a promising treatment for 
chronic pain for patients with late diagnosis. We have also shown that FKBP51 could be 
targeted to reduce the hypersensitivity seen in a murine model of chemotherapy-induced 
peripheral neuropathy (CIPN), even when given once the pain state was fully established. 
CIPN is a common debilitating side effect of anticancer drugs and unfortunately, with no 
treatment options for CIPN, clinicians often need to reduce the dose of the 
chemotherapeutic agent or discontinue its use [30], which leads to poorer survival rates. 
Our data suggest that FKBP51 inhibition could provide pain relief to cancer patients treated 
with paclitaxel and therefore offer hope for prolonged anti-cancer treatments.  
 
5 CONCLUSIONS 
In conclusion, we have demonstrated that FKBP51 is an exciting new pharmacological target 
for the treatment of chronic pain states across sexes. Inhibition of FKBP51 with the state-of-
the-art ligand SAFit2 reduced the hypersensitivity that develops following ankle joint 
inflammation, nerve injury and paclitaxel treatment. These long-term pain states have 
distinct underlying mechanisms, suggesting that FKBP51 could be targeted for the treatment 
of a large number of persistent pain states across sexes. Moreover, when encapsulated in 
VPG, a single injection of SAFit2 led to a long-lasting relief of hypersensitivity indicating a 
strong translational potential for chronic treatment by FKBP51 inhibition. Importantly, 
individuals with variants in the FKBP5 gene have altered pain sensitivity after trauma [7], 
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lending confidence that pharmacological inhibition of FKBP51 could indeed help patients 
suffering with chronic pain. 
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FIGURE LEGENDS 
Fig.1: FKBP51 regulates long-term joint inflammatory pain states in female mice by 
modulation of glucocorticoid signalling. (A) Mechanical sensitivity in female KO and WT 
mice after injection of CFA in the ankle joint (n=8/8) (2-way ANOVA, TIME B3 to D14, factor 
“Genotype”: F1,14 = 11.3, P<0.01). B: baseline; D: day. Data show means ± SEM. *P<0.05, 
**P≤0.01, WT vs KO; post-hoc one-way ANOVA. (B) RT-qPCR analysis of FKBP51, IL6 and GRβ 
in the dorsal horn 3 days after CFA injection in the ankle joint; data normalized to WT sham 
(For FKBP51 data, ANOVA: F2,18 = 3.53; P<0.05; post hoc analysis LSD P<0.05. For GRβ data, 
ANOVA: F2,18 = 3.44; P<0.05 post hoc analysis LSD P<0.05. For IL6 data, ANOVA: F2,18 = 2.72; 
P<0.1; post hoc analysis LSD P<0.05.) Data show means ± SEM. *P<0.05. (C) RU38486 
(mifepristone, GR antagonist) effect on CFA-induced mechanical hypersensitivity in female 
WT mice and female KO mice (n=4/7). WT/vehicle vs WT/RU38486: 2-way ANOVA, 1h-D4, 
factor “Treatment”: F1,9 = 5.4, P<0.05; KO/vehicle vs KO/RU38486: 2-way ANOVA, TIME B2 
to 1h, factor “Treatment”: F3,18 = 3.3, P<0.05). B: baseline; D: day. Data show means ± SEM. 
*P<0.05: WT/vehicle vs WT/RU38486; #P<0.05: KO/vehicle vs KO/RU38486; results of post-
hoc one way ANOVA. 
Fig.2: FKBP51 regulates neuropathic pain states across sexes and is often seen in neurones 
and sometimes in astrocytes in the superficial dorsal horn. (A) Mechanical sensitivity in 
female and male KO and WT mice after SNI (n=6 per group) (2-way ANOVA, TIME D1 to D14, 
factor “Genotype”: F1,19 = 39.6, P<0.0001. 2-way ANOVA female only, TIME D1 to D14, factor 
“Genotype”: F1,9 = 21.4, P<0.001. 2-way ANOVA male only, TIME D1 to D14, factor 
“Genotype”: F1,10 = 17.8, P<0.01). (B-C) FKBP51 immunoreactivity 7 days after SNI surgery. 
FKBP51 was often seen in neurones (stained with NeuN, blue, B-C), sometimes in astrocytes 
AC
CE
PT
ED
8 8            
32 
(stained with Gfap, red, B) and very rarely in microglia (stained with Iba1, red, C). B-C: Cyan: 
To-pro, nuclear marker; scale bar: 15µm. Arrows indicate astrocytes or microglia positive for 
FKBP51; arrowheads indicate microglia negative for FKBP51. (D-G) X-Gal stain confirming 
that FKBP51 (blue) is mainly expressed in neurones (brown, D-E) and very rarely in microglia 
(brown, F-G). Scale bar: 100µm; arrows indicate neurones or microglia positive for X-gal; 
arrowheads indicate microglia negative for FKBP51. 
Fig.3: FKBP51 regulates the mechanical hypersensitivity seen in a model of paclitaxel 
induced pain. (A) Mechanical sensitivity in WT mice after paclitaxel or vehicle treatment 
(n=7/5) (2-way ANOVA, TIME D4 to D8, factor “Treatment”: F1,10 = 6.6, P<0.01). (B) 
Mechanical sensitivity in male KO and WT mice after paclitaxel treatment (n=6/6) (2-way 
ANOVA, TIME D1 to D12, factor “Genotype”: F1,10 = 34.8, P<0.0001). Data show means ± 
SEM. *P<0.05, **P<0.01, ***P<0.001, results of post-hoc one-way ANOVA. (C) RT-qPCR 
analysis of FKBP51, IL6 and GRβ in the dorsal horn 10 days after PTX injection (n=5/5); data 
normalized to WT sham; *P<0.05.  
Fig.4: Pharmacological blockade of FKBP51 reduces the mechanical hypersensitivity seen 
in long-term pain states in both male and female mice. (A) Single subcutaneous injection of 
SAFit2 3 days after CFA in the ankle joint in WT males (n=4/4) (2-way ANOVA, TIME D3 to 
28h, factor “Treatment”: F1,5=21.6, P<0.01). (B) Single subcutaneous injection of SAFit2 5 
days after SNI in males (n=4/4) (2-way ANOVA, TIME D5 to D7, factor “Treatment”: 
F1,6=7.98, P<0.05. (C) Repeated systemic i.p. injection of SAFit2 3 days after CFA in the ankle 
joint in males (n=6/8) (2-way ANOVA, TIME D1 to D11, factor “Treatment”: F1,12 = 6.8, 
P<0.05). (D) Repeated systemic i.p. injection of SAFit2 5 days after SNI in males (n=6/8) (2-
way ANOVA, TIME D1 to D13, factor “Treatment”: F1,12 = 8.8, P<0.05). IP injections in (C) and 
(D): SAFit2 2mg/ml in Vehicle A. (E) Single subcutaneous injection of SAFit2-VPG (n=5/5) in 
females (SAFit2 10mg/ml, 10ml/kg in Vehicle B) 5 days after SNI (2-way ANOVA, TIME D7 to 
D13, factor “Treatment”: F1,8 = 17.1, P<0.01). (F) Single subcutaneous injection of SAFit2 5 
days after SNI in females (n=4/4) (2-way ANOVA, TIME D5 to D7, factor “Treatment”: F1,6 = 
6.0, P<0.05) (SAFit2 10mg/ml, 10ml/kg in Vehicle C). (G) Single subcutaneous injection of 
SAFit2-VPG in naïve WT mice. (H) Single subcutaneous injection of SAFit2-VPG 3 days after 
CFA in the ankle joint in KO mice. (G-H): N=3 per group. (I) Single subcutaneous injection of 
SAFit2-VPG (n=6/6) in male after paclitaxel (SAFit2 10mg/ml, 10ml/kg in Vehicle B) (2-way 
ANOVA, TIME D14 to D20, factor “Treatment”: F1,10 = 10.3, P<0.01). Arrows indicate IP 
injections: pointing-down arrows, Paclitaxel injection; pointing-up arrow, SAFit2-VPG. (J) 
Repeated subcutaneous injection of SAFit2-VPG (n=8/8) in males 12 days after SNI (SAFit2 
10mg/ml, 10ml/kg in Vehicle B). SAFit2-VPG was injected on D12 and D19; (2-way ANOVA, 
TIME D15 to D26, factor “Treatment”: F1,6=48.3, P<0.001). (A-J): B: baseline; D: day. (E, F, I 
and J): the purple band highlights a period of 5 days starting 48h after SAFit2 injection. Data 
show means ± SEM. *P<0.05, **P<0.01, ***P<0.001, results of post-hoc one-way ANOVA. 
SAFit2 or vehicle injection time is indicated by vertical arrows (small arrow for SAFit2 and 
big arrow for SAFit2-VPG). 
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Table 1: Corticosterone levels in FKBP5 KO and WT mice before and after nerve injury. Plasma 
corticosterone levels are expressed in ng/ml. Data show mean ± SEM. 2-way ANOVA, Factor 
Genotype F1,15 = 11.3, P<0.01; Factor “Time” F2,15 = 4.8, P<0.05; post-hoc analysis: LSD. *P<0.05, 
**P<0.01, WT vs KO within each time point. 
#
P<0.05: vs naïve within each genotype. Female mice. 
N=2-4. 
 
 
Naïve 5d post SNI 14d post SNI 
FKBP5 KO 116.4 ± 40.5 * 322.4 ± 122.9  113.7 ± 34.1 ** 
WT 217.0 ± 27 * 465.8 ± 54.5 
#
 522.8 ± 183.5 **, 
#
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